Clinical Takeaway
In this phase 3 randomized controlled trial of 820 adults with chronic low back pain, the full-spectrum cannabis extract VER-01 was evaluated against placebo over 12 weeks with extended follow-up reaching 15 months. The trial design is rigorous, including both a blinded phase and a randomized withdrawal period, providing a meaningful test of durability alongside initial efficacy. Results from this study carry direct clinical relevance for patients who have not responded adequately to conventional pharmacologic options for chronic low back pain.
#1 Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.
Citation: Karst Matthias et al.. Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.. Nature medicine. 2025. PMID: 41023483.
Design: 5 Journal: 4 N: 2 Recency: 2 Pop: 2 Human: 1 Risk: -2
This phase 3 trial addresses a critical clinical gap by providing rigorous efficacy and safety data for a full-spectrum cannabis extract in chronic low back pain, a condition affecting over 500 million people globally where current pharmacotherapies demonstrate limited effectiveness and significant adverse effect profiles. The inclusion of a 12-week double-blind phase followed by extended open-label observation strengthens the evidence base needed to inform clinical decision-making and regulatory approval pathways for cannabis-derived therapeutics in a common, burdensome chronic pain condition. These findings could establish a pharmacologically distinct treatment option for patients who fail or cannot tolerate conventional analgesics, potentially reducing opioid-related morbidity in a population with high medication burden
Quality Gate Alerts:
- Preclinical only
Methodological Considerations:
- Open-label design — placebo effect not excluded
Abstract: Chronic low back pain (CLBP) affects over half a billion people worldwide. Current pharmacologic treatments offer limited efficacy and carry substantial risks, warranting the development of safe and effective alternatives. This multicenter, randomized, placebo-controlled phase 3 trial evaluated the efficacy and safety of VER-01 in CLBP. It enrolled 820 adults with CLBP (VER-01, n = 394; placebo, n = 426) and included a double-blind 12-week treatment phase (phase A), a 6-month open-label extension (phase B), followed by either a 6-month continuation (phase C) or randomized withdrawal (phase D). The primary endpoint of phase A was a change in mean numeric rating scale (NRS) pain intensity, with a change in total neuropathic pain symptom inventory (NPSI) score as a key secondary endpoint in participants with a neuropathic pain component (PainDETECT > 18). The primary endpoint for phase D was time to treatment failure. The study met its primary endpoint in phase A, with a mean pain reduction of -1.9 NRS points in the VER-01 group (mean difference (MD) versus placebo = -0.6, 95% confidence interval (CI) = -0.9 to -0.3; P < 0.001). Pain further decreased to -2.9 NRS points in phase B, with effects sustained through phase C. The study also met its key secondary endpoint of phase A, with a mean NPSI decrease of -14.4 (standard error, 3.3) points from baseline in the VER-01 arm (MD versus placebo = -7.3, 95% CI = -13.2 to -1.3; P = 0.017). Although phase D did not meet its primary endpoint (hazard ratio = 0.75, 95% CI = 0.44-1.27; P = 0.288), pain increased significantly more with placebo upon withdrawal (MD = 0.5, 95% CI = 0.0-1.0; P = 0.034). In phase A, the incidence of adverse events-mostly mild to moderate and transient-was higher with VER-01 than with placebo (83.3% versus 67.3%; P < 0.001). VER-01 was well-tolerated, with no signs of dependence or withdrawal. VER-01 shows potential as a new, safe and effective treatment for CLBP. ClinicalTrials.gov registration: NCT04
💊 This phase 3 trial of VER-01, a full-spectrum cannabis extract, adds meaningful data to an understudied area where conventional analgesics often fall short in chronic low back pain management. The study’s rigorous design with 820 participants and structured follow-up strengthens confidence in whatever efficacy signals emerge, though we should note that full-spectrum extracts contain variable cannabinoid and terpene profiles that may complicate both reproducibility and individualized dosing in clinical practice. The inclusion of a 6-month open-label extension phase is valuable for safety assessment but also introduces potential bias toward continuation in responders, so the relative contribution of active drug versus expectancy effects warrants careful interpretation of the published results. Important confounders include concurrent physical therapy, psychological comorbidities, and prior opioid exposure, which typically influence CLBP outcomes substantially and may or may not be adequately stratified. For practitioners considering cannabis-based options in selected patients with refractory chronic low back pain, awa